Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
Open Access
- 25 November 2024
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 732-741
Abstract
Adagrasib is a potent, highly selective, orally available, small molecule, covalent inhibitor of G12C mutated KRAS. As both a substrate and strong inhibitor of cytochrome P450 (CYP) 3A4, adagrasib inhibits its own CYP3A4‐mediated metabolism following multiple dosing, resulting in time‐dependent drug–drug interaction (DDI) liabilities. A physiologically‐based pharmacokinetic (PBPK) model was developed and verified using a combination of physicochemical, in vitro and clinical pharmacokinetic (PK) data from healthy volunteers and cancer patients. The PBPK model well‐described the single and multiple‐dose adagrasib PK data as well as DDI data with itraconazole, rifampin, midazolam, warfarin, dextromethorphan, and digoxin, with model predictions within 1.5‐fold of the observed clinical data. The PBPK model was used to predict untested scenarios including the clinical victim and perpetrator DDI liabilities at the approved dosing regimen of 600 mg twice daily (b.i.d.) in cancer patients. Strong, moderate, and weak inhibitors of CYP3A4 are predicted to have a negligible effect on the steady‐state exposure of adagrasib 600 mg b.i.d. resulting from the significant inactivation of CYP3A4 by adagrasib. Additionally, strong and moderate inducers of CYP3A4 are predicted to decrease adagrasib exposure by 68% and 22%, respectively. As a perpetrator, adagrasib 600 mg b.i.d. is predicted to be a strong inhibitor of CYP3A4, a moderate inhibitor of CYP2C9 and CYP2D6, and an inhibitor of P‐glycoprotein (P‐gp). These results successfully supported regulatory interactions with the United States Food and Drug Administration regarding dosing recommendations for when adagrasib is used concomitantly with other medications, supporting a range of label claims in lieu of clinical trials.Keywords
This publication has 19 references indexed in Scilit:
- Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and FutureClinical Pharmacology & Therapeutics, 2024
- Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic PerspectivePharmaceutical Research, 2022
- Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizationsCPT: Pharmacometrics & Systems Pharmacology, 2022
- Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration’s Office of Clinical PharmacologyJournal of Pharmaceutical Sciences, 2019
- Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium PerspectiveClinical Pharmacology & Therapeutics, 2018
- Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic ModelingClinical Pharmacology & Therapeutics, 2016
- Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspectiveClinical Pharmacology & Therapeutics, 2015
- Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug AdministrationClinical Pharmacokinetics, 2014
- Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterionsJournal of Pharmaceutical Sciences, 2006
- Effect of Altered Plasma Protein Binding on Apparent Volume of DistributionJournal of Pharmaceutical Sciences, 1979